Clinical Trials Directory

Trials / Completed

CompletedNCT00002032

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
750 (planned)
Sponsor
Pharmacia · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200 cells/mm3. To investigate the incidence of MAC in these patients. A secondary objective is to compare clinical response, quality of life (Karnofsky), and survival between these two groups.

Conditions

Interventions

TypeNameDescription
DRUGRifabutin

Timeline

First posted
2001-08-31
Last updated
2005-06-24

Locations

33 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00002032. Inclusion in this directory is not an endorsement.

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = (NCT00002032) · Clinical Trials Directory